Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events.

Trial Profile

EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Cinacalcet (Primary)
  • Indications Cardiovascular disorders; Heart failure; Secondary hyperparathyroidism
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors Amgen
  • Most Recent Events

    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 11 Jun 2015 Results of post hoc analysis have been published in the Circulation.
    • 04 Jun 2015 Results published in the Journal of Human Hypertension.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top